CFU-Mk content of immunoselected CD34+ peripheral blood progenitor cells, evaluated with an adapted serum-free methylcellulose assay, is predictive of platelet lineage reconstitution in children with solid tumors

被引:9
作者
Boiret, N
Kanold, J
Fouassier, M
Bons, JM
Halle, P
Rapatel, C
Berger, J
Pireyre, P
Blanzat, V
Travade, P
Bonhomme, J
Demeocq, F
Berger, MG
机构
[1] Fac Med & Pharm, Hematol Lab, SEHM, F-63001 Clermont Ferrand 1, France
[2] Serv Pediat B, Unite Bioclin & Traitement Cellules Souches Hemat, F-63000 Clermont Ferrand 1, France
来源
JOURNAL OF HEMATOTHERAPY & STEM CELL RESEARCH | 2000年 / 9卷 / 04期
关键词
D O I
10.1089/152581600419206
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Immunoselected CD34(+) peripheral blood progenitor cell (PBPC) transplantation is now frequently used to support autologous hematopoiesis after myeloablative therapy, its feasability having been proved by several groups. However, we and others observed delayed platelet recovery. We hypothesized that immunoselection processing might induce selective loss of megakaryocyte progenitors, or a decrease in their proliferation. We used a colony-forming units megakaryocyte (CFU-Mk) assay to evaluate these consequences and predict platelet recovery in patients. In CD34(+) PBPCs from 10 children with solid tumors, we observed no selective loss in CFU-Mk numbers during immunoselection processing and no impairment of clonogenicity. The CFU-Mk yield (59.2 +/- 11.3%) was at least similar to the CD34(+) yield (44.2 +/- 3.8%). We assessed the predictive value of CPU-Mk numbers infused for recovery of platelet lineage. We found an inverse correlation between the time taken to reach a platelet count greater than 50 x 10(9)/L and only the CFU-Mk dose (r = -0.71; p 0.022) among the different type of progenitors, including colony-forming units granulocyte-macrophage (CPU-GM), burst-forming units erythrocyte (BFU-E) and colony-forming units-mixed (CFU-Mix). These findings suggest that CFU-Mk number could be used as sole predictive functional parameter for platelet reconstitution in children after immunoselection of CD34(+) cells, in particular for low CD34(+) cell dose, and thus as an indicator for initial quality of hematopoietic cells before in vitro expansion.
引用
收藏
页码:525 / 534
页数:10
相关论文
共 53 条
  • [1] Changes of telomere length in children after hematopoietic stem cell transplantation
    Akiyama, M
    Hoshi, Y
    Sakurai, S
    Yamada, H
    Yamada, O
    Mizoguchi, H
    [J]. BONE MARROW TRANSPLANTATION, 1998, 21 (02) : 167 - 171
  • [2] ANDREWS RG, 1986, BLOOD, V68, P1030
  • [3] FACTORS THAT INFLUENCE COLLECTION AND ENGRAFTMENT OF AUTOLOGOUS PERIPHERAL-BLOOD STEM-CELLS
    BENSINGER, W
    APPELBAUM, F
    ROWLEY, S
    STORB, R
    SANDERS, J
    LILLEBY, K
    GOOLEY, T
    DEMIRER, T
    SCHIFFMAN, K
    WEAVER, C
    CLIFT, R
    CHAUNCEY, T
    KLARNET, J
    MONTGOMERY, P
    PETERSDORF, S
    WEIDEN, P
    WITHERSPOON, R
    BUCKNER, CD
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1995, 13 (10) : 2547 - 2555
  • [4] BENSINGER W, 1993, BLOOD, V81, P3158
  • [5] BERENSON RJ, 1991, BLOOD, V77, P1717
  • [6] Feasibility of a PB CD34(+) cell transplantation procedure using standard leukapheresis products in very small children
    Berger, M
    Kanold, J
    Rapatel, C
    deLumley, L
    Lutz, P
    Plantaz, D
    Vannier, JP
    Mechinaud, F
    Bergeron, C
    Favrot, M
    Gembara, P
    HalleHauss, P
    Bonhomme, J
    Travade, P
    Demeocq, F
    [J]. BONE MARROW TRANSPLANTATION, 1997, 20 (03) : 191 - 198
  • [7] SERUM-FREE MEDIUM ALLOWS THE OPTIMAL-GROWTH OF HUMAN MEGAKARYOCYTE PROGENITORS COMPARED WITH HUMAN PLASMA SUPPLEMENTED CULTURES - ROLE OF TGF-BETA
    BERTHIER, R
    VALIRON, O
    SCHWEITZER, A
    MARGUERIE, G
    [J]. STEM CELLS, 1993, 11 (02) : 120 - 129
  • [8] Bojko P, 1998, J CLIN APHERESIS, V13, P7, DOI 10.1002/(SICI)1098-1101(1998)13:1<7::AID-JCA2>3.0.CO
  • [9] 2-D
  • [10] POSITIVELY SELECTED AUTOLOGOUS BLOOD CD34+ CELLS AND UNSEPARATED PERIPHERAL-BLOOD PROGENITOR CELLS MEDIATE IDENTICAL HEMATOPOIETIC ENGRAFTMENT AFTER HIGH-DOSE VP16, IFOSFAMIDE, CARBOPLATIN, AND EPIRUBICIN
    BRUGGER, W
    HENSCHLER, R
    HEIMFELD, S
    BERENSON, RJ
    MERTELSMANN, R
    KANZ, L
    [J]. BLOOD, 1994, 84 (05) : 1421 - 1426